Could Erector Spinae Block Transform Pain Management After Scoliosis Surgery?

Could ESPB Transform Postoperative Pain Control?

The Potential of Erector Spinae Plane Block for Postoperative Pain Management in Scoliosis Correction Surgery: A New Clinical Trial

A new clinical trial is set to investigate whether bilateral ultrasound-guided erector spinae plane block (ESPB) provides superior postoperative pain control compared to conventional patient-controlled intravenous analgesia (PCIA) in patients undergoing scoliosis correction surgery. The single-center, prospective randomized controlled trial, registered as NCT06728046, will be conducted at West China Hospital, Sichuan University, with recruitment scheduled to begin in January 2025. This study aims to address a critical challenge in spinal surgery: managing severe postoperative pain while minimizing opioid-related side effects that can impair recovery and extend hospitalization.

What Challenges Does Scoliosis Surgery Present?

Scoliosis correction surgery is associated with extensive surgical wounds spanning multiple vertebrae, requiring significant muscle dissection and resulting in intense postoperative pain. In a multicenter cohort study involving over 115,000 patients across 179 surgical procedures, spinal fusion ranked among the top three procedures for postoperative pain severity. While patient-controlled analgesia with intravenous opioids remains the standard approach for pain management, this conventional model frequently leads to side effects such as postoperative nausea and vomiting, pruritus, dizziness, and potential respiratory depression. These complications can limit the efficacy of pain control and negatively impact patients' recovery trajectory. The Enhanced Recovery After Surgery (ERAS) strategy has emerged as a benchmark for promoting postoperative recovery, with multimodal analgesia serving as a fundamental component that incorporates various drugs and techniques to manage pain while minimizing opioid-related complications.

How Does ESPB Work and What Are Its Advantages?

The erector spinae plane block, first described by Forero et al. in 2016, has garnered increasing attention as a novel regional anesthesia technique. The procedure involves ultrasound-guided injection of local anesthetic into the fascial plane between the erector spinae muscle and the transverse process of the vertebra. This allows the anesthetic to diffuse anteriorly into paravertebral and epidural spaces and laterally into intercostal spaces across several vertebral levels, effectively blocking both ventral and dorsal rami of the spinal nerves. ESPB offers several advantages: it is relatively simple to perform, accommodates lower coagulation function, and features a puncture site positioned safely away from the spinal cord, minimizing the risk of spinal cord injury and other complications. Previous studies have demonstrated ESPB's effectiveness in reducing postoperative pain scores, decreasing opioid consumption, and lowering the incidence of nausea and vomiting in various surgical settings, including some spinal procedures.

How Is the Trial Structured?

The upcoming trial will randomize 40 patients (20 per group) scheduled for idiopathic scoliosis correction surgery to receive either bilateral bilevel ultrasound-guided ESPB or standard PCIA with sufentanil. Eligible participants include patients aged 14 years or older with American Society of Anesthesiologists (ASA) physical status I-III who are scheduled for scoliosis correction surgery. Exclusion criteria encompass allergy to local anesthetics, family history of malignant hyperthermia, severe systemic diseases, neurological or psychiatric disorders, coagulation abnormalities, and communication difficulties. In the ESPB group, patients will receive the block in prone position before intubation. The affected spinal segment will be divided into three equal parts, with puncture sites selected at the trisection points on each side. A total of 40 mL of 0.3% ropivacaine will be administered, with 20 mL injected on each side. The PCIA group will receive a standard postoperative regimen with 200 μg sufentanil diluted to 100 ml, administered with a background dose of 3 ml/h, a lockout time of 15 minutes, and a bolus dose of 2 ml. Both groups will receive general anesthesia with standard monitoring and maintenance protocols, and rescue analgesia will be available for patients with inadequate pain control.

What Outcomes Are Being Measured?

The primary outcome of the study will be the resting numerical rating scale (NRS) pain score at 2 hours postoperatively. Secondary outcomes include resting and movement NRS pain scores on postoperative days 1-3, postoperative opioid consumption, time to initiate functional exercises, hospital length of stay, and total hospital costs. The researchers will also monitor and grade complications according to a five-tier severity classification system. Statistical analysis will employ a modified intention-to-treat principle, with two-way repeated measures analysis of variance for pain score comparisons and appropriate parametric or non-parametric tests for other variables.

Why Is This Research Clinically Relevant?

This trial addresses an important clinical need, as the majority of patients undergoing scoliosis correction surgery are adolescents or younger children who exhibit heightened sensitivity to pain stimuli. Poorly controlled postoperative pain can significantly impair mobility, delay functional recovery, and increase the risk of complications such as deep vein thrombosis and pulmonary infections. The global prevalence of idiopathic scoliosis ranges from 0.47% to 5.20%, with adolescent idiopathic scoliosis accounting for approximately 90% of all cases. Despite the widespread clinical application of ESPB, its underlying mechanism of action, the extent of drug diffusion, and optimal dosing regimen remain controversial. The researchers plan to incorporate baseline variables such as body weight, height, surgical duration, and spinal segment locations in their subgroup analyses to help identify trends and inform hypotheses for future larger studies.

What Are the Study’s Limitations?

The study has several acknowledged limitations. The open-label design may lead to selection bias, allocation bias, or measurement bias, potentially influencing various phases of the trial. Additionally, as a single-center study with only 40 patients, it cannot adequately represent populations from other regions. To enhance the reliability and generalizability of the findings, future research should aim to expand the sample size and increase the number of participating centers. The researchers also highlight the need for developing predictive models or applying stratified analyses to refine ESPB protocols based on patient-specific anatomical and procedural variables.

Could These Findings Shape Future Practice?

The findings could have significant implications for clinical practice in the management of postoperative pain following complex spinal surgeries. Could the integration of ESPB into multimodal analgesic protocols fundamentally change our approach to pain management in these challenging cases? How might personalized approaches, such as dose adjustments based on body weight or surgical span, enhance the efficacy and safety of regional anesthesia techniques? What regulatory challenges might arise in implementing this therapy as a standard of care across different healthcare settings? As healthcare continues to emphasize enhanced recovery and opioid-sparing strategies, this trial may provide valuable evidence for improving pain management, enhancing healthcare quality, and improving the overall patient experience in scoliosis correction surgery.

Summary

A new clinical trial at West China Hospital will investigate whether bilateral ultrasound-guided erector spinae plane block (ESPB) provides superior postoperative pain control compared to conventional patient-controlled intravenous analgesia in patients undergoing scoliosis correction surgery. The study, registered as NCT06728046 and beginning recruitment in January 2025, will randomize 40 patients to receive either bilateral ESPB with ropivacaine or standard opioid-based analgesia. Scoliosis correction surgery ranks among the most painful procedures, with extensive tissue trauma spanning multiple vertebrae, and current opioid-based approaches frequently cause side effects including nausea, vomiting, and respiratory depression that impair recovery. ESPB, first described in 2016, involves injecting local anesthetic into the fascial plane between the erector spinae muscle and vertebral transverse process, allowing diffusion across multiple spinal levels to block ventral and dorsal nerve rami. The technique offers advantages including technical simplicity, safety from the spinal cord, and accommodation of patients with lower coagulation function. The trial will measure resting pain scores at 2 hours postoperatively as the primary outcome, with secondary outcomes including pain scores over three days, opioid consumption, time to functional exercises, hospital length of stay, and costs. This research addresses a critical need, as most scoliosis surgery patients are adolescents with heightened pain sensitivity, and poorly controlled pain can delay mobility, increase complications, and prolong hospitalization. Study limitations include the open-label design and small sample size from a single center, necessitating larger multicenter trials to confirm findings and establish optimal protocols.